Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

Merle, PhilippePhilippeMerleKudo, MasatoshiMasatoshiKudoEdeline, JulienJulienEdelineBouattour, MohamedMohamedBouattourANN-LII CHENGChan, Stephen LStephen LChanYau, ThomasThomasYauGarrido, MarceloMarceloGarridoKnox, JenniferJenniferKnoxDaniele, BrunoBrunoDanieleBreder, ValeriyValeriyBrederLim, Ho YeongHo YeongLimOgasawara, SadahisaSadahisaOgasawaraCattan, StéphaneStéphaneCattanChao, YeeYeeChaoSiegel, Abby BAbby BSiegelMartinez-Forero, IvánIvánMartinez-ForeroWei, ZiwenZiwenWeiLiu, Chih-ChinChih-ChinLiuFinn, Richard SRichard SFinn2023-10-312023-10-312023-092235-1795https://scholars.lib.ntu.edu.tw/handle/123456789/636694KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported.enHepatocellular carcinoma; Long-term follow-up; Pembrolizumab; Programmed cell death protein 1[SDGs]SDG3Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trialjournal article10.1159/000529636379012002-s2.0-85163701825https://api.elsevier.com/content/abstract/scopus_id/85163701825